Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation
Author:
Affiliation:
1. Division of Nephrology; Boston Children's Hospital; Boston MA USA
2. Department of Pediatrics; Harvard Medical School; Boston MA USA
3. Herscot Center for TSC and Division of Pediatric Nephrology; Massachusetts General Hospital; Boston MA USA
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.428/fullpdf
Reference51 articles.
1. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US oncology network;Vogelzang;Clin Genitourin Cancer,2013
2. Research and innovation in the development of everolimus for oncology;Lebwohl;Expert Opin Drug Discov,2011
3. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization;Sehgal;J Antibiot (Tokyo),1975
4. Indications and management of everolimus after liver transplantation;Bilbao;Transplant Proc,2009
5. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors;Buck;Mol Cancer Ther,2006
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tuberous Sclerosis Complex and the kidneys: what nephrologists need to know;Brazilian Journal of Nephrology;2024-09
2. Complexo da Esclerose Tuberosa e rins: o que os nefrologistas devem saber;Brazilian Journal of Nephrology;2024-09
3. Rapamycin prevents cyclophosphamide-induced ovarian follicular loss and potentially inhibits tumour proliferation in a breast cancer xenograft mouse model;Human Reproduction;2024-05-11
4. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group;Nature Reviews Nephrology;2024-03-05
5. Abnormal Endometrial Receptivity and Oxidative Stress in Polycystic Ovary Syndrome;Frontiers in Pharmacology;2022-07-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3